pAAV-CMV-CASANOVA
(Plasmid
#113036)
-
PurposeAAV vector for CASANOVA (AcrIIA4-LOV2 hybrid) expression in mammalian cells; enables optogenetic control of SpyCas9
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 113036 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonescAAV vector
- Total vector size (bp) 4973
-
Vector typeMammalian Expression, AAV, CRISPR, Synthetic Biology
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameCASANOVA (for CRISPR/Cas9 activity switching via a novel optogenetic variant of AcrIIA4)
-
Alt nameengineered AcrIIA4-LOV2 hybrid for optogenetic control of CRISPR/SpyCas9
-
Alt nameinhibits SpyCas9 in the absence of light and releases Cas9 activity upon photoactivation
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Addgene Next-Generation Sequence analysis identified numerous sequence discrepancies in ITR sequences. Plasmid is expected to function as described in the associated publication: PMID: 30377362
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pAAV-CMV-CASANOVA was a gift from Dominik Niopek (Addgene plasmid # 113036 ; http://n2t.net/addgene:113036 ; RRID:Addgene_113036) -
For your References section:
Engineered anti-CRISPR proteins for optogenetic control of CRISPR-Cas9. Bubeck F, Hoffmann MD, Harteveld Z, Aschenbrenner S, Bietz A, Waldhauer MC, Borner K, Fakhiri J, Schmelas C, Dietz L, Grimm D, Correia BE, Eils R, Niopek D. Nat Methods. 2018 Oct 30. pii: 10.1038/s41592-018-0178-9. doi: 10.1038/s41592-018-0178-9. 10.1038/s41592-018-0178-9 PubMed 30377362